Note 13 - Business Segment Reporting

12 Months Ended

Dec. 31, 2022

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

13. Business Segment Reporting

The Company manages its operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all the financial information related to the Company’s principal operating segment. The Company’s revenues by geographic region, based on the location of the customer, were as follows (in thousands):

	Year Ended December 31,
	2022		2021		2020
Consolidated Revenue:
United States	$	24,509	$	23,584	$	19,486
International		731		1,325		1,874
Total Revenue	$	25,240	$	24,909	$	21,360